poss. buy signal soon on the daily....take a look at the gap to fill....also dvax blurb today
Long suffering Dynavax Technologies (DVAX) is up over 6% in mid-day trading as the company revealed Tuesday evening that immunogenicity and safety results from two Phase 3 Heplisav trials were published in Vaccine. Heplisav is meant to treat Hepatitis B. This clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases seems like a solid speculative play here.
At $1.25 a share, the stock is significantly below the ~$4 a share median price target held by the four analysts that cover DVAX (low target: $1.50 a share, high target: $5 a share). The company also has some $90mm in net cash (~35% of market capitalization) which is over 2 years of funding at current burn rates. Insiders are not selling any shares and I believe the stock makes for a good speculative selection for aggressive investors.
